AstraZeneca to Buy Gracell Advancing Cell Therapy Ambition
AstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreThe MANDARA Phase III trial marks the first head-to-head comparison of biologics in treating eosinophilic granulomatosis with polyangiitis (EGPA), putting
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreEli Lilly and Company and DICE Therapeutics, Inc. have signed a definitive agreement for Lilly to acquire DICE for approximately $2.4
Read moreCoya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read moreAccording to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read moreMyMD Pharmaceuticals, Inc.®, a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
Read moreCompugen will present new research at AACR 2023 that allows for the accurate detection and study of novel target PVRIG.
Read morePfizer and BioNTech plan to use mRNA technology to meet the demand for highly effective, well-tolerated, and effectively manufactured shingles
Read more